Green Alpha Advisors LLC Has $627,000 Holdings in Illumina, Inc. (NASDAQ:ILMN)

Green Alpha Advisors LLC increased its position in Illumina, Inc. (NASDAQ:ILMN) by 82.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 4,693 shares of the life sciences company’s stock after purchasing an additional 2,127 shares during the period. Green Alpha Advisors LLC’s holdings in Illumina were worth $627,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Versant Capital Management Inc boosted its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. TD Private Client Wealth LLC boosted its position in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares during the period. Massmutual Trust Co. FSB ADV grew its stake in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Illumina in the 2nd quarter valued at about $61,000. Finally, Private Trust Co. NA increased its holdings in shares of Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock valued at $62,000 after purchasing an additional 212 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on ILMN shares. TD Cowen boosted their price objective on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $190.00 to $165.00 in a research note on Wednesday, December 11th. Stephens increased their price objective on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Royal Bank of Canada boosted their target price on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $156.00 price target on shares of Illumina in a research note on Tuesday, November 12th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $165.95.

Illumina Stock Down 2.1 %

ILMN stock opened at $136.69 on Monday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a 50-day moving average of $141.11 and a two-hundred day moving average of $132.61. The stock has a market capitalization of $21.68 billion, a price-to-earnings ratio of -13.72 and a beta of 1.11. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.33 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.